Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge acts for EQT and the subsidiary company ESML Intressenter in connection with the takeover bid for Securitas Direct
Mandate

Vinge acts for EQT and the subsidiary company ESML Intressenter in connection with the takeover bid for Securitas Direct

November 13, 2007

Vinge is acting for EQT and the subsidiary company, jointly owned by EQT, SäkI AB, Melker Schörling AB and Investment AB Latour, in connection with the public cash offer to the shareholders of Securitas Direct AB. The offer also includes an offer to the holders of subscription options in Securitas Direct AB. Securitas Direct AB is listed on the OMX Nordic Stock Exchange. Vinge assists with stock exchange and corporate advice, financing, and acquisition structuring. The total value of the offer is appr. 9.6 billion kronor.

The Vinge team includes Hans Wibom, Michael Wigge, Ola Sandersson, Christoffer Saidac, Tuula Tallavaara, Dain Nevonen and Martin Hall. Fabian Ekeblad and Louise Salomon assist with the financing and Johan Karlsson and Peter Forsberg assist with the competition filing.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025